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AbstrACt
background A pilot study of stereotactic body radiation 
therapy (SBRT) followed by high- dose interleukin-2 (IL-
2) showed a higher than anticipated objective response 
rate (ORR) among patients with metastatic melanoma 
(MM). We performed a prospective randomized study to 
determine if the ORR of SBRT + IL-2 was greater than IL-2 
monotherapy in patients with advanced melanoma.
Methods Patients with MM who had adequate 
physiological reserve for IL-2 and at least one site suitable 
for SBRT were eligible. There was a 1:1 randomization to 
SBRT + IL-2 or IL-2 monotherapy. Patients received one or 
two doses of SBRT (20 Gy per fraction) with the last dose 
administered 3 days before starting the first cycle of IL-2. 
IL-2 (600,000 IU per kg via intravenous bolus infusion) 
was given every 8 hours for a maximum of 14 doses with 
a second cycle after a 2- week rest. Responding patients 
received up to six IL-2 cycles. Patients assigned to IL-2 
monotherapy who exhibited progression of melanoma 
after cycle 2 were allowed to crossover and receive SBRT 
and additional IL-2. Response Evaluation Criteria in Solid 
Tumors 1.1 criteria were applied to non- irradiated lesions 
for response assessment.
results 44 patients were included in the analysis. The 
ORR in the SBRT + IL-2 group was 54%: 21% complete 
response (CR), 33% partial response (PR), 21% stable 
disease (SD) and 25% progressive disease (PD). The ORR 
in patients receiving IL-2 monotherapy was 35%: 15% CR, 
20% PR, 25% SD and 40% PD. Seven patients assigned to 
IL-2 subsequently received SBRT + IL-2. One CR and two 
PRs were observed in the crossover group. There was no 
difference in progression- free or overall survival (OS). At 5 
years the OS was 26% in the SBRT + IL-2 group and 25% 
in the IL-2 monotherapy group. The disease control rate 
(DCR) was higher in the SBRT + IL-2 group (75% vs 60%, 
p=0.34).
Conclusions SBRT + IL-2 induced more objective 
responses with a higher DCR compared to IL-2 
monotherapy in MM. IL-2 monotherapy resulted in 
a significantly higher ORR than anticipated. Some 
patients in the crossover group also achieved objective 
responses.
trial registration number NCT01416831.
bACkground
The first publication reporting the efficacy 
of high- dose (HD) interleukin-2 (IL-2) for 
patients with metastatic melanoma appeared 
in 1985; a subsequent manuscript describing 
270 patients treated with HD IL-2 reported 
a complete response (CR) rate of 6% and 
a partial response (PR) rate of 10% with a 
median duration of response greater than 40 
months.1 2 Over 70% of patients achieving a 
CR and approximately 15% of those achieving 
a PR were alive and without recurrence at 15 
years identifying HD IL-2 as the first curative 
immunotherapy regimen for patients with 
stage IV melanoma. Since 2010 there have 
been many significant advances in mela-
noma treatment including the development 
of checkpoint antibodies, first anti- CTLA-4 
using ipilimumab,3 then anti- PD-1 with 
nivolumab,4 and now the use of combined 
T- cell checkpoint therapy with ipilimumab 
and nivolumab showing an objective response 
of 58% and complete response of 19% asso-
ciated with 3- year survival of 52%.5 Clinically 
significant responses and disease control 
have also been demonstrated with anti- PD-1 
checkpoint monotherapy with nivolumab or 
pembrolizumab.6 7 Targeted therapy with the 
BRAF and MEK inhibitors vemurafenib and 
cobimetinib, dabrafenib and trametinib or 
cobimetinib and encorafenib are also asso-
ciated with a high probability of objective 
response and improvement of disease- free 
and overall survival. Complete regressions 
with BRAF- targeted therapy are also possible 
and associated with improved long- term 
outcomes.8 Improved survival has been vali-
dated for T- cell checkpoint inhibitor (CPI) 
therapy and BRAF- targeted therapy combi-
nations, yet the proportion of patients with 
complete and durable responses who require 
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subsequent therapy based on progression- free survival 
probability is at least 60% and may be as high as 80% at 
3 years.5 6 Furthermore, the best therapy or therapeutic 
sequence for patients who have melanoma progression 
after CPI or targeted therapy is not yet known and most 
patients with metastatic disease still die as a consequence 
of melanoma as illustrated by recent survival statistics.9
Preclinical studies indicate that exposure of tumor cells 
to high- dose radiation can augment the release of inflam-
matory cytokines, upregulate expression of MHC class I, 
B7.1, and Fas/CD95.10–15 Tumor cells injured by radiation 
can also release damage- associated molecular patterns 
(DAMPs) such as HMGB1 and double- stranded DNA 
(dsDNA) that can trigger a TLR4- dependent cognate 
immune response.16 High- dose per fraction radiation also 
increases tumor infiltrating activated CD8+ T cells and has 
been associated with enhanced tumor control at distant 
sites when combined with immunomodulatory agents in 
preclinical studies.17–19
We observed that patients with melanoma or renal cell 
carcinoma (RCC) who had radiation for urgent palliation 
in the week before IL-2 had a surprisingly high objec-
tive response in lesions that were not radiated following 
high- dose IL-2. This observation led us to perform a 
pilot phase I trial of stereotacticbody radiation therapy 
(SBRT) and IL-2 in which the primary objective was to 
determine the maximum tolerated dose (MTD) of SBRT. 
We observed an objective response of 71% in previously 
untreated patients with metastatic melanoma and 60% in 
RCC. There was no increase in the toxicities associated 
with high- dose IL-2 and no dose- limiting toxicities asso-
ciated with radiation. These encouraging initial clinical 
signals were the basis for the phase II trial reported here.
The primary clinical aim of the phase II study was to 
compare the objective response of SBRT + IL-2 versus IL-2 
monotherapy in the non- irradiated lesions. Secondary 
objectives included an evaluation of crossover to SBRT + 
IL-2 in patients who progressed on IL-2, and an investiga-
tion of DAMPs, which as stated above may be important 
immune adjuvants that influence the response to immu-
notherapy and radiation. Due to the technical complex-
ities of measuring HMGB-1 dsDNA in the peripheral 
blood, we chose instead to measure surrogate markers 
for DAMPs including uric acid, lactate dehydrogenase 
(LDH) and phosphorus, which reflect cell and DNA 
damage after radiation and procalcitonin, which reflects 
tissue injury and cytokine induction.
This study started in late 2011, which was the time that 
T- cell checkpoint antibodies and BRAF- targeted therapy 
were entering clinical practice. The availability of these 
melanoma treatment options significantly influenced 
accrual to this clinical trial and the clinical histories of 
the study population as detailed below.
Methods
study design and population
A single institution phase II study was conducted at the 
Earle A. Chiles Research Institute, Providence Portland 
Medical Center (PPMC), Providence Cancer Institute. 
The main eligibility criteria were patients >18 years old, 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0 to 1, histological confirmation of mela-
noma, at least one metastatic lesion amenable to SBRT 
in the lung, mediastinum or liver, and at least one other 
metastatic site not treated with SBRT. Cardiopulmonary 
status sufficient to tolerate HD IL-2 was required20 and 
patients had essentially normal hematologic, hepatic, 
and renal function before treatment. Exclusion criteria 
included having no metastatic site amenable to SBRT; 
active infection; previous radiation to sites proposed for 
SBRT; need for chronic steroids or active autoimmune 
disease. Signed informed consent was obtained prior to 
enrollment. The study was listed on  Cancer. gov. There 
were no restrictions for prior melanoma systemic thera-
pies or for brain metastases as long as they were stable or 
improved after local therapy (surgery and/or stereotactic 
radiation).
Procedures
SBRT planning was performed using a four- dimensional 
CT scan with the patient in the treatment position immo-
bilized with the BodyFIX (Elekta, Atlanta, Georgia). The 
internal target volume was delineated on the planning CT 
and a 3 to 5 mm planning target volume margin was used. 
An intensity modulated radiation therapy treatment plan 
with 6 MV photons was generated using Pinnacle V.9.0 
software (Philips Medical Systems, Andover, Massachu-
setts) based on tumor location and geometry. The target 
was localized with cone beam CT before each treatment, 
which was delivered on the Synergy S (Elekta, Atlanta, 
Georgia) machine. A minimum of one and a maximum of 
three lesions were treated with SBRT. Clinical criteria were 
used to select the lesion(s) to be treated with radiation. 
Lesions that were causing pain or compressing a hollow 
viscus (such as bronchus or bile duct) were prioritized 
over others. In patients where no symptoms were being 
caused by their metastatic sites, then the lesion deemed 
safest to administer radiation was selected. A maximum 
diameter of 7 cm was allowed for each SBRT target lesion. 
All patients were treated by two of the authors (SKS and 
MC). The first eight patients were treated with one SBRT 
dose on the Friday before the Monday on which IL-2 was 
to start. The subsequent 16 patients were treated with two 
SBRT doses to the target lesion on the Wednesday and 
Friday before the Monday IL-2 start. The protocol was 
modified due to the observation that a melanoma patient 
treated with one SBRT dose had progression of the radi-
ated lesion.
Patients who signed informed consent were assigned to 
treatment group in a 1:1 proportion using randomization 
by the closed envelope method. Of the 50 patients who 
signed consent, six were excluded (three due to rapid 
melanoma progression during screening, two due to 
cardiac ischemia on exercise tolerance testing and one 
due to insurance issues).
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Interleukin-2 (Prometheus Pharmaceuticals, Dallas, 
Texas) treatment began on the Monday following the last 
radiation treatment and was administered at 600,000 IU 
per kilogram intravenousbolus infusion every 8 hours × 
14 planned doses with an additional cycle given after a 
16- day hiatus (two cycles=one course of IL-2). Imaging 
was obtained after each course and patients with tumor 
regression could receive up to three courses. After IL-2 
was completed, imaging was obtained every 3 months 
until progression or 24 months of follow- up. If patients 
did not have progression at 24 months, then imaging was 
obtained every 4 months through 3 years after the start 
of IL-2 and then every 6 months in year 4 and thereafter. 
Patients assigned to the IL-2 monotherapy group and 
who showed progression of melanoma after course 1 
could receive SBRT and additional IL-2 cycles contingent 
on response. We employed PPMC Biotherapy Program 
guidelines for IL-2 management, which are a modifica-
tion of published IL-2 dosing rules.20 21
This protocol used a modified version of the Response 
Evaluation Criteria in Solid Tumors (RECIST) V.1.1.22 
The overall response assessment included all measurable 
and non- measurable target lesions except the lesions 
treated by SBRT, which were assessed separately. Both 
CT and positron emission tomography imaging were 
employed to assess response. A further modification of 
RECIST criteria was used to assess tumor bulk as reported 
in online supplementary figure 3 (absolute spider plots). 
The sum of the long axis diameter of the largest 30 tumor 
deposits was added and compared over time.
Markers of tumor lysis, inflammation and immune 
activation were explored by measuring serum lactate 
dehydrogenase, procalcitonin, uric acid and phosphate 
as surrogate markers of cytotoxicity- mediated antigen 
release with measurements obtained at baseline, after 
radiation but before IL-2 and after IL-2 was completed 
in cycle 1.
outcomes
The primary study endpoint was to determine the best 
overall tumor response rate of high dose IL-2 versus 
SBRT + high- dose IL-2 using RECIST criteria applied 
to all target and non- target lesions with the exclusion 
of sites treated with SBRT. We assumed in designing the 
study that the objective response to IL-2 monotherapy 
would be 16% based on other published data23 while 
the response to SBRT + IL-2 would be 60% based on 
our initial pilot study.24 Using the Pearson χ2 test with 
continuity correction, enrolling 22 patients per group 
(44 total) would have an 80% power to detect a differ-
ence using the response assumptions detailed above. For 
patients who received SBRT after progression on IL-2 
monotherapy, the response rate was recorded, but not 
counted in the assessment of overall tumor response for 
the primary objective. The secondary objectives were 
hypothesis generating and were not included in deter-
mining the sample size.
statistical analysis
Baseline characteristics were compared using Fisher’s 
exact tests and Wilcoxon rank- sum test for continuous 
and categorical variables, respectively. The endpoint for 
overall survival (OS) was the time from the date treat-
ment started to death. The endpoint for progression- 
free survival (PFS) was the time between the start of IL-2 
treatment to the event related to the disease (progressive 
disease (PD) after initial CR, PR or stable disease (SD)) 
or death. To examine whether there was a difference in 
OS and PFS between two treatment groups, Kaplan- Meier 
and Cox proportional- hazards regression analyses were 
performed. The association of age, gender, LDH, BRAF 
status with OS and PFS were also evaluated. In addition, 
logistic regression analyses were employed to determine 
the independent predictors of disease control rate (DCR) 
(CR/PR/SD). All statistical analyses were performed 
using R V.3.5.0 (R Core Team, 2018).
results
Population
Forty- four eligible patients with advanced melanoma 
enrolled and were treated from August 2011 through 
March 2017. Twenty- four patients were randomized to 
receive SBRT + IL-2 and 20 patients were assigned to 
IL-2 monotherapy. Of the eight patients randomized to 
IL-2 whose melanoma progressed after the first imaging, 
seven agreed to participate in the crossover portion of 
the study. Five additional patients signed consent but 
withdrew consent before receiving treatment as they 
opted for other systemic therapies and were not included 
in this analysis. Table 1 summarizes clinical character-
istics and treatments before and after IL-2. There were 
no statistically significant differences in demographic 
characteristics, or baseline tumor burden, although 
patients assigned to the SBRT + IL-2 group tended to 
have a greater tumor burden compared with the IL-2 
monotherapy group (online supplementary table 1). The 
mean LDH among patients assigned to SBRT + IL-2 was 
389 compared with 263 IU/L in patients assigned to IL-2 
monotherapy (upper limit of normal 268 IU/L). A higher 
proportion of patients in the IL-2 monotherapy cohort 
had melanomas with a BRAF V600E mutation compared 
with those assigned to SBRT + IL-2 (55% vs 29%, p=0.1).
outcomes
Figure 1 shows waterfall plots of best overall response 
using RECIST 1.1 criteria after SBRT + IL-2 of the target 
lesions not treated with SBRT (1A) and IL-2 monotherapy 
(1B). The objective response in the SBRT + IL-2 group 
was 21% CR, 33% PR, 21% SD and 25% PD. Among the 
patients who received SBRT + IL-2, the best response 
was determined after course 1 in eight patients (33%), 
after course 2 in eight patients (33%) and after course 
3 in eight patients (33%). Patients receiving IL-2 mono-
therapy had 15% CR, 20% PR, 25% SD and 40% PD. The 
DCR was 75% in the SBRT+IL-2 group and 60% in the IL-2 
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Table 1 Clinical characteristics and treatments of study 
participants by group
SBRT + IL-2 IL-2
Male 18 16
Female 6 4
Age (mean) 53 57.5
BRAF status
  Mutated/wild type/unknown 7/14/3 11/5/4
Baseline LDH (mean) (upper 
limit of normal 268 IU/L)
389 263
Prior therapy
  Surgery (%) 24 (100) 20 (100)
  Radiation (n) 1 (4) 3 (15)
  BRAF therapy (n) 1 0
  Immune checkpoint (n) 5 3
Subsequent therapy
  BRAF therapy (n) 4 5
  Immune checkpoint (n) 11 6
Metastatic sites at start of treatment
  Lung (%) 64 74
  Liver (%) 36 37
  Lymph node (%) 36 53
  Bone (%) 14 5
  Subcutaneous (%) 27 11
  Brain (%) 5 5
  Soft tissue (%) 50 21
  Adrenal (%) 14 0
Sum of diameters of target lesions using modified RECIST
  cm (median) 8.2 6.5
  cm (mean) 5.1 5.3
Sum of diameters of 30 largest lesions
  cm (median) 19.7 13.7
  cm (mean) 11.4 10.7
LDH, lactate dehydrogenase; RECIST, Response Evaluation 
Criteria in Solid Tumors.
Figure 1 (A) Waterfall plot of best response to SBRT + IL-2. 
The radiated lesions were excluded from RECIST assessment 
of target lesions. The responses of patients who participated 
in the crossover portion of the study are excluded from 
this analysis. (B) Waterfall plot of best response, IL-2 
monotherapy before crossover. The responses to additional 
IL-2 cycles after crossover are excluded. IL-2,interleukin-2; 
RECIST, Response Evaluation Criteria inSolid Tumors; SBRT, 
stereotactic body radiation therapy.
monotherapy group (p=0.34). Among the patients who 
received IL-2 monotherapy, the best response was deter-
mined after course 1 in 11 patients (55%), after course 2 
in two patients (10%) and after course 3 in seven patients 
(35%). Seven patients assigned to IL-2 monotherapy 
participated in the crossover. One patient achieved a CR 
and two achieved PR of the lesions not treated with SBRT. 
Progression- free survival is depicted in figure 2A and 
overall survival in figure 2B. There was no difference in 
progression- free or overall survival among the treatment 
groups. The 1- year, 3- year and 5- year survivals were 71%, 
41% and 26%, respectively, in the SBRT + IL-2 group. 
For the IL-2 monotherapy group (including crossover 
patients), the 1- year, 3- year and 5- year survivals were 65%, 
35% and 25%, respectively. The 1- year, 3- year and 5- year 
survivals for IL-2 monotherapy excluding the crossover 
group were 62%, 46% and 29%, respectively.
The clinical outcomes and subsequent treatments of 
all 44 patients over time are summarized using swimmers 
plots (figure 3A for the SBRT + IL-2 group and figure 3B 
for IL-2 monotherapy + crossover groups). Of the 24 
patients assigned to the SBRT + IL-2 cohort, four received 
BRAF- targeted therapy and 14 received CPI at the time of 
progression. This includes the 13 patients who achieved 
an initial CR or PR by RECIST criteria to SBRT + IL-2. 
Of the seven patients who achieved an initial CR or PR 
after IL-2 monotherapy, four required subsequent treat-
ments. Five patients received CPI therapy before SBRT 
+ IL-2 and three before IL-2 monotherapy. Five of the 
eight patients receiving CPI before enrolling on this trial 
had responses to IL-2, two of which were durable (lasting 
more than 1 year). Seven of the 18 patients who received 
CPI after SBRT + IL-2 had a partial regression of disease 
including one crossover patient. The 11 patients who did 
not achieve a PR with subsequent CPI had a brief interval 
of stability followed by progression of their melanoma. 
One of three patients who received IL-2 monotherapy 
(and no radiation) achieved a PR with subsequent CPI. 
Of the seven patients participated in the crossover, five 
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Figure 2 (A) Kaplan- Meier plot of progression- free survival by treatment group. Patients who participated in the crossover 
group are included with the IL-2 group. (B) Kaplan- Meier plot of overall survival by treatment group. Patients who participated in 
the crossover group are included in the IL-2 group. IL-2,interleukin-2; OS, overall survival; PFS, progression- freesurvival; SBRT, 
stereotactic body radiationtherapy.
received BRAF- targeted therapy and five received CPI at 
the time of melanoma progression. Two patients in the 
SBRT + IL-2 group and three patients assigned to the 
IL-2 monotherapy group have not required additional 
systemic or local treatments for their melanoma.
As described by others, patients with higher than normal 
baseline LDH levels had a lower probability of response 
(p=0.08). We also performed an analysis of the response 
of individual tumor lesions based on the clinical obser-
vation that many patients experienced mixed responses 
with regression of some lesions and progression or the 
development of new lesions. This analysis did not change 
the response interpretation as defined by RECIST. Online 
supplemental figures S1−S3 illustrate the tumor response 
in relation to the absolute tumor burden (sum of long- 
axis diameters of all lesions on CT).
response of lesions treated with sbrt
Patients received SBRT either as part of their initial cohort 
assignment before cycle 1 IL-2 or if they progressed 
after IL-2 monotherapy and opted to participate in the 
crossover group. Crossover patients received SBRT 
before cycle 3 of HD IL-2. When the protocol started 
enrolling patients, only one SBRT dose was specified as 
there appeared to be no difference in the outcome of 
patients in the completed pilot study comparing one, 
two or three SBRT doses before IL-2.24 However, among 
the patients assigned to a single SBRT dose we observed 
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Figure 3 (A) Swimmers plot for SBRT + IL-2 patients. Each bar represents an individual patient’s treatment history with the bar 
color indicating survival status and subsequent treatment. (B) Swimmers plot for IL-2 patients (including crossover). Each bar 
represents an individual patient’s treatment history with the bar color indicating participation in the crossover, survival status 
and subsequent treatment. IL-2,interleukin-2; SBRT, stereotactic body radiation therapy.
rapid progression of a liver lesion. The protocol was 
modified to administer two SBRT doses thereafter. Eight 
patients assigned to the SBRT + IL-2 group received one 
SBRT dose and 16 patients received two SBRT doses. 
Six of the seven patients in the crossover group received 
two SBRT doses. Table 2 summarizes the characteristics 
of the lesions treated with SBRT. The median diameter 
of lesions in patients assigned to the SBRT cohort was 
smaller compared with the patients who participated 
in the crossover (2.5 vs 4.5 cm, p=0.08). There was no 
significant difference in the organ site selection for SBRT 
comparing the groups. Among patients who experienced 
regression of tumors at the non- irradiated sites, the 
median size of the lesions treated with SBRT was 1.6 cm 
compared with 2.9 cm in patients whose lesions in non- 
irradiated sites did not regress. Of the 31 tumors treated 
in the SBRT cohort, 27 decreased in size (15 complete 
and 12 partial responses using RECIST criteria) and 4 
increased in size. In the crossover group, nine lesions 
were treated of which seven decreased (three complete 
and four partial responses of the irradiated lesions) and 
two increased. We also investigated the degree and dura-
tion of responses in non- irradiated lesions in relation to 
the site chosen for SBRT (summarized in table 3). The 
study was not powered to detect differences in response 
based on the site selected for SBRT; however, we observed 
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Table 2 Characteristics of the lesions treated with SBRT.
SBRT SBRT crossover
Median lesion size (cm)
Baseline (range) 2.5 (0.5 to 6.4) 4.3 (1.6 to 7.1)
Assessment 1 1.3 (0 to 5.5) 2.5 (0 to 7.5)
Assessment 2 0 (0 to 6.1) 2.5 (0 to 6.3)




Lung (%) 14 (45) 2
Liver (%) 11 (35) 4
LN (%) 4 (13) 3
Other (%) 2 (6) 0
Lesions that progressed (%)* 5 (16) 2 (22)
Lesions that regressed (%) 25 (81) 7 (78)
Lesions with no change (%) 1 (3) 0 (0)
Lesions BORR=0 (%) 15 (48) 3 (33)
#, number; BORR, best overall response rate; LN, lymph node; SBRT, 
stereotactic body radiation therapy.
Table 3 Response of non- irradiated lesions in relation to SBRT treated site
SBRT site (n)








Liver (7) –77, 13, –100, 4, 119, −100, 18 4 −18 289, 188, 350, 162, 57, 306, 69 188
Lung (10) −62, 0, –100, 14, 89, 38, –23, 
–100, 41, 0
0 −11 767, 105, 399, 81, 342, 83, 39, 
1238, 67, 169
169
Lymph node (4) –57, –100, –100, –47 −78.5 −76 76, 1726, 690, 258 474
Bone (1) −53 −53 −53 334 334
Liver + lung (1) −100 −100 −100 793 793
Lung + bone (1) −67 −67 −67 129 129
SBRT, stereotactic body radiation therapy.







Liver (2) –100, –100 −100 −100 157, 278 217
Lung (2) –100, –18 −59 −41 377, 168 272
Lymph node (1) 56 56 56 56 56
Liver + lung (1) −12 −12 −12 83 83
no difference in response based on 1 versus >1 site radi-
ated or the number of radiation fractions (50% vs 56%). 
There was a trend favoring response of irradiating lung 
tumors versus liver lesions or other sites (58% vs 33%).
treatment received and safety
The median number of IL-2 doses for the first and second 
cycles of therapy were 10 and 7 in the SBRT + IL-2 group 
and 9 and 8 in the IL-2 monotherapy group (p=NS). This 
was comparable to the median number of IL-2 doses 
tolerated historically by other patients in our Biotherapy 
Program who did not receive SBRT.21
Anticipated toxicities from IL-2 were observed and 
included hypotension requiring vasopressor support, 
pulmonary capillary leak with hypoxemia, fever, rigors, 
myalgias, arthralgias, pruritus, erythematous rash, diar-
rhea, nausea, electrolyte abnormalities, elevations of 
hepatocellular enzymes, azotemia, peripheral neurop-
athy, mental status changes and immune- mediated hypo-
thyroidism. These toxicities were transient (with the 
exception of immune- mediated hypothyroidism) and 
resolved using supportive medications and holding IL-2 
doses. There were no long- lasting toxicities from IL-2 with 
the exception of hypothyroidism requiring levothyroxine 
in 16 patients and vitiligo in 6 patients, all of whom had 
regression of melanoma during treatment.
One patient assigned to the SBRT + IL-2 cohort devel-
oped respiratory failure after cycle 2 IL-2 characterized 
by patchy infiltrates in both lungs and outside the radi-
ation ports in the right lateral and left anterior lung 
fields. He did not improve on broad- spectrum antibiotics 
or after diuresis, bronchodilators, empiric steroids and 
mechanical ventilation. Multiple cultures did not reveal 
an infectious etiology. Imaging revealed regression of 
some of the melanoma deposits in the lungs including 
the lesions treated with SBRT as well as other pulmo-
nary metastatic sites. The clinical differential diagnoses 
included atypical pneumonia, lymphangitic spread of 
melanoma or immune- mediated lung injury. In light of 
the patients advanced melanoma, the patient opted for 
best supportive care and he died as a consequence of 
respiratory failure. The patient did not consent to inva-
sive procedures for biopsy and his family declined to have 
an autopsy performed.
Peripheral blood dAMPs
Surrogate markers for DAMPs including uric acid, LDH, 
procalcitonin and phosphorus were measured serially 
and compared by treatment assignment. Figure 4 shows 
baseline and peak values for uric acid and procalcitonin. 
Responding patients who received SBRT displayed a 
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Figure 4 (A) Uric acid (mg/dL) by treatment group comparing baseline and peak values during cycle 1. In most patients, the 
peak uric acid value occurred on day 5 or 6 after IL-2 started. There was no statistically significant difference in the timing or the 
peak uric acid level comparing SBRT + IL-2 or IL-2 monotherapy although there was a trend toward high uric acid levels among 
SBRT + IL-2 responders compared with non- responders. (B) Baseline and peak procalcitonin (ng/ml) by treatment group during 
cycle 1. The peak procalcitonin was observed on day 5 or 6 after IL-2 started. There was no statistically significant difference in 
the timing or the peak procalcitonin level comparing SBRT + IL-2 or IL-2 monotherapy although there was a trend toward lower 
procalcitonin levels among SBRT + IL-2 responders compared with non- responders. IL-2, interleukin-2; SBRT, stereotacticbody 
radiation therapy.
trend toward higher median uric acid and lower median 
procalcitonin levels on days 5 and 6 after the start of IL-2 
compared with patients who did not have a response 
to SBRT + IL-2 or those assigned to IL-2 monotherapy. 
There were no statistically significant changes in any of 
the DAMP surrogate markers measured due to patient- to- 
patient variation.
disCussion
The combination of SBRT and IL-2 showed a trend toward 
higher response and higher DCR compared with IL-2 
monotherapy in patients with advanced melanoma yet 
no statistically significant differences in PFS or OS were 
observed. We were surprised to observe the much higher 
than anticipated objective response of the IL-2 mono-
therapy arm. As expected, some patients in both arms 
achieved durable regressions of their melanoma and did 
not require further systemic or local therapy; however, 
the majority of patients required subsequent medical, 
surgical or radiation therapy to manage their melanoma. 
Overall, the duration of response in each group was less 
than anticipated based on prior reports with IL-2 mono-
therapy from our group and others.21 25 The shorter than 
anticipated response duration may have been due to prior 
therapy altering the immune response or the responsive-
ness of the melanoma to an IL-2- based regimen. Although 
overall survival could not be compared due to the cross-
over design, the 1- year, 3- year and 5- year survivals for 
patients in both arms were clinically relevant. The overall 
survival at 1, 3 and 5 years after CPI or BRAF- targeted 
therapy independent of IL-2 immunotherapy in patients 
with advanced melanoma is significant, yet the reality for 
the majority of patients is that multiple lines of systemic 
therapy are needed. Our long- term results are similar to 
more contemporary reports of patients receiving high- 
dose IL-2. For instance, Davar et al, describe 1- year, 2- year 
and 3- year survivals of 41%, 20% and 14%, respectively, 
in a large single- institution study comprising 243 patients 
with advanced melanoma.26 After progression on IL-2, 36 
patients were treated with T- cell checkpoint antibodies and 
7 (19%) have ongoing response to immunotherapy. The 
long- term survival of patients in both treatment groups in 
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this study was probably influenced by subsequent therapy 
in light of the current knowledge about survival benefit of 
CPI and BRAF- targeted therapies. Similarly, anti- PD-1 and 
anti- CTLA-4 before IL-2 likely influenced IL-2 responses. 
Although no prospective study on clinical outcome exists 
for the activity of checkpoint inhibitors after IL-2, retro-
spective observations suggest a higher than anticipated 
response to anti- PD-1 following IL-2.25 In this report, 18% 
of patients achieved partial regressions of melanoma after 
their high- dose IL-2 regimen.
The rationale for investigating the combination of high- 
dose per fraction radiation and IL-2 was not based on the 
assumption of an abscopal effect. Rather, we hypothesized 
that cell death from radiation supplied a source of antigen 
for adaptive immune response and that the IL-2 provided 
a strong cytokine signal to amplify immune response.27 
As a consequence of the radiation- induced cell death, 
we also expected to observe higher uric acid levels in 
patients who received radiation. In addition, we hypoth-
esized that procalcitonin would be lower as the immune 
response would be directed to the radiated tumor and 
not manifest systemically as is the case with high- dose 
IL-2. There were no statistically significant differences 
among the treatment groups due to significant patient- to- 
patient variation, but there was a trend toward higher uric 
acid and lower procalcitonin in responding SBRT + IL-2 
patients compared with non- responders for IL-2 mono-
therapy. The study was not designed to detect a difference 
in clinical outcome based on the site chosen for SBRT, 
but none of the patients who had liver as the only site 
treated with SBRT achieved control of melanoma. The 
mechanism for this lack of response may be related to 
fewer CD8 + T cells present in liver metastases and also 
decreased CD8 + T cell in tumor- infiltrating lymphocytes 
in non- liver sites in melanoma patients having liver metas-
tases.28 The patients who had a pulmonary site chosen for 
SBRT had the highest proportion of response. Individual 
patients who had both a lung and liver site also achieved 
responses. This observation may be a consequence of the 
known poorer prognosis of patients who have melanoma 
liver metastases compared with melanoma lung metas-
tases. It also suggests that the immune response after 
radiation in pulmonary sites may be different compared 
with radiation of hepatic sites. We are developing a clin-
ical trial to investigate this hypothesis.
We acknowledge the small sample size, the influence 
of the crossover in interpreting response and survival 
and the lengthy time to meet accrual goals; however, the 
medical management of advanced melanoma changed 
dramatically from the time the study opened in late 
2011 to the present with at least nine new medicines 
or regimens approved by the Food and Drug Adminis-
tration. These changes in melanoma treatment altered 
the referral patterns to our cancer center of untreated 
patients compared with our original pilot study, which 
treated patients in the first line with SBRT + IL2.24
ConClusions
We observed a modest trend toward higher response 
rates with SBRT + IL-2 and higher disease control rate in 
patients receiving dual therapy compared with IL-2 mono-
therapy. A larger study without a crossover group would 
be required to address overall survival in the current 
era of melanoma treatment in which multiple lines of 
therapy are commonly administered to patients with 
advanced melanoma. This study also illustrates that SBRT 
+ IL-2 has activity in patients after progression on IL-2 
monotherapy, CPI or BRAF- targeted therapy, the latter 
of which are the current standards of care for patients 
with advanced melanoma. Individuals with symptomatic 
metastatic sites amenable to treatment with high- dose per 
fraction radiation and physiological reserve sufficient to 
tolerate HD IL-2 should be considered for SBRT + IL-2 in 
the second or third line.
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